Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study.
Pseudomonas aeruginosa
bacterial resistance
carbapenem
cefiderocol
respiratory tract infection
Journal
Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893
Informations de publication
Date de publication:
30 Jan 2021
30 Jan 2021
Historique:
received:
30
12
2020
revised:
25
01
2021
accepted:
28
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Cefiderocol is a novel siderophore cephalosporin, which has proven in vitro activity against carbapenem-resistant (CR) Gram-negative pathogens and stability towards all carbapenemases. The aim of this study was to describe the first cases of prescriptions and the efficacy of cefiderocol for compassionate use in the 2 months following its access in France. We performed a national retrospective study of all patients who received at least one dose of cefiderocol from 2 November 2018 to 5 November 2019. We collected clinical characteristics and outcome through a standard questionnaire. Bacterial isolates from 12 patients were centralized and analyzed in the French National Reference Center for Antimicrobial Resistance, and sequenced using Illumina technology. Finally, 13 patients from 7 French university hospitals were included in the study. The main type of infection treated by cefiderocol was respiratory tract infections (RTI,
Identifiants
pubmed: 33573148
pii: microorganisms9020282
doi: 10.3390/microorganisms9020282
pmc: PMC7911443
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29158270
Lancet Infect Dis. 2021 Feb;21(2):226-240
pubmed: 33058795
Drugs Context. 2018 May 29;7:212527
pubmed: 29872449
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32727829
J Clin Microbiol. 2020 Dec 17;59(1):
pubmed: 32938734
Clin Infect Dis. 2020 Sep 17;:
pubmed: 32941593
Expert Rev Anti Infect Ther. 2018 Feb;16(2):89-110
pubmed: 29310479
Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150
pubmed: 30046639
Antimicrob Agents Chemother. 2017 Jan 24;61(2):
pubmed: 27855079
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S544-S551
pubmed: 31724049